These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 8188083

  • 21. Estrogen receptor immunocytochemical assay (ERICA) and laminin detection in 130 breast carcinomas and computerized (Samba 200) multiparametric quantitative analysis on tissue sections.
    Charpin C, Martin PM, Lissitzky JC, Jacquemier J, Kopp F, Pourreau-Schneider N, Lavaut MN, Toga M.
    Bull Cancer; 1986; 73(6):651-64. PubMed ID: 3567371
    [Abstract] [Full Text] [Related]

  • 22. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
    Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J, Danish Breast Cancer Cooperative Group.
    J Clin Oncol; 2008 Mar 20; 26(9):1419-26. PubMed ID: 18285604
    [Abstract] [Full Text] [Related]

  • 23. Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c.
    Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Andersen J, Overgaard J.
    Acta Oncol; 2008 Mar 20; 47(4):591-9. PubMed ID: 18465327
    [Abstract] [Full Text] [Related]

  • 24. Immunohistochemical staining of estrogen and progesterone receptors: aspects for evaluating positivity and defining the cutpoints.
    Jalava P, Kuopio T, Huovinen R, Laine J, Collan Y.
    Anticancer Res; 2005 Mar 20; 25(3c):2535-42. PubMed ID: 16080489
    [Abstract] [Full Text] [Related]

  • 25. Quantitative immunohistochemical assay for hormonal receptors: technical aspects and biological significance.
    Esteban JM, Ahn C, Battifora H, Felder B.
    J Cell Biochem Suppl; 1994 Mar 20; 19():138-45. PubMed ID: 7823586
    [Abstract] [Full Text] [Related]

  • 26. [The immunohistochemical growth fraction (Ki-67) of breast cancers: relations to tumor spread, tumor morphology and receptor testing].
    Weikel W, Beck T, Rosenthal H, Herzog R.
    Geburtshilfe Frauenheilkd; 1989 Mar 20; 49(3):277-82. PubMed ID: 2566552
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Estrogen receptor analysis on biopsies and fine-needle aspirates from human breast carcinoma. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.
    Reiner A, Spona J, Reiner G, Schemper M, Kolb R, Kwasny W, Függer R, Jakesz R, Holzner JH.
    Am J Pathol; 1986 Dec 20; 125(3):443-9. PubMed ID: 3541638
    [Abstract] [Full Text] [Related]

  • 29. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype.
    Rakha EA, El-Sayed ME, Green AR, Paish EC, Powe DG, Gee J, Nicholson RI, Lee AH, Robertson JF, Ellis IO.
    J Clin Oncol; 2007 Oct 20; 25(30):4772-8. PubMed ID: 17876012
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
    Voogd AC, Crommelin MA, Repelaer van Driel OJ, Tutein Nolthenius-Puylaert MC, Vreugdenhil G, Coebergh JW.
    Ned Tijdschr Geneeskd; 1998 Aug 01; 142(31):1772-8. PubMed ID: 9856143
    [Abstract] [Full Text] [Related]

  • 33. [Estrogen and progesterone receptors of primary breast carcinoma and their axillary lymph node metastases--immunohistochemical investigations of routine formalin-fixed paraffin-embedded tissue].
    Schulze MH, Buchmann J.
    Zentralbl Gynakol; 2000 Aug 01; 122(2):92-5. PubMed ID: 10721188
    [Abstract] [Full Text] [Related]

  • 34. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
    Arpino G, Weiss HL, Clark GM, Hilsenbeck SG, Osborne CK.
    J Clin Oncol; 2005 Jul 20; 23(21):4687-94. PubMed ID: 15837971
    [Abstract] [Full Text] [Related]

  • 35. Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival.
    Pertschuk LP, Masood S, Simone J, Feldman JG, Fruchter RG, Axiotis CA, Greene GL.
    Gynecol Oncol; 1996 Oct 20; 63(1):28-33. PubMed ID: 8898164
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Estrogen receptor status in breast carcinoma. Results of comparative immunohistochemical and biochemical studies].
    Köhler G, Bässler R.
    Dtsch Med Wochenschr; 1986 Dec 19; 111(51-52):1954-60. PubMed ID: 3024947
    [Abstract] [Full Text] [Related]

  • 39. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G, Regan MM, Maiorano E, Mastropasqua MG, Golouh R, Perin T, Brown RW, Kovács A, Pillay K, Ohlschlegel C, Braye S, Grigolato P, Rusca T, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS.
    J Clin Oncol; 2008 Mar 20; 26(9):1404-10. PubMed ID: 18349391
    [Abstract] [Full Text] [Related]

  • 40. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
    Derin D, Eralp Y, Ozluk Y, Yavuz E, Guney N, Saip P, Igci A, Ozmen V, Kücücük S, Aslay I, Aydiner A, Topuz E.
    Cancer Invest; 2008 Aug 20; 26(7):671-9. PubMed ID: 18608215
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.